Jean Dinh

simcyp ltd/certara

H指数:10

被引数:628

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Managing Drug–Drug Interactions Involving the Non-Prescription Opioid Loperamide Through Physiologically Based Pharmacokinetic Modeling

cpt: pharmacometrics & systems pharmacology

IF0

2026-01-210

OAAI

The rational use of PBPK to assess the changing DDI liability in Pediatrics: Model Qualification and the Move Towards Best Practice.

基于PBPK模型的合理应用以评估儿科患者中DDI风险的变化：模型资质认证及向最佳实践的转变。

Drug Metabolism and Pharmacokinetics

IF2.2

2025-11-260

PRE

Development, Verification, and Application of a Chinese Pediatric Physiologically Based Pharmacokinetic Model: Emphasis on CYP Metabolism and Renal Elimination

中国儿科生理药代动力学模型的开发、验证与应用：强调CYP代谢和肾脏消除

The AAPS Journal

IF0

2025-11-100

PRE

Investigating Sulfotransferase Mediated Drug Interactions of Ethinylestradiol using a Physiologically Based Pharmacokinetic Model

使用生理药代动力学模型研究乙炔基雌二醇的磺基转移酶介导的药物相互作用

The AAPS Journal

IF0

2025-11-040

PRE

Development and Verification of Virtual Population Models for Predicting Drug Pharmacokinetics in Ethnic North American Populations

虚拟人群模型的开发与验证：用于预测民族北美人群的药物药代动力学

cpt pharmacometrics systems pharmacology

IF0

2025-07-170

OAAI

Postpartum changes in maternal physiology and milk composition: a comprehensive database for developing lactation physiologically-based pharmacokinetic models

产后母体生理变化与乳汁成分变化：用于开发基于泌乳生理的药动学模型的综合数据库

FRONTIERS IN PHARMACOLOGY

IF4.8

2025-02-030

Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta-9-Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes

通过多种途径给药后，健康成年人的大麻二酚，Delta-9-Tetrahydrocannabinol及其代谢物的生理药代动力学模型

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2025-01-021

OAAI

Combining data on the bioavailability of midazolam and physiologically-based pharmacokinetic modeling to investigate intestinal CYP3A4 ontogeny

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-06-261

OAAI

Physiologically Based Pharmacokinetics Modeling in the Neonatal Population-Current Advances, Challenges, and Opportunities

PHARMACEUTICS

IF5.5

2023-11-035

OAAI

Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-08-1110

OAAI

Managing Drug Interactions Involving the Over-the-Counter Opioid Loperamide through Physiologically Based Pharmacokinetic Modeling

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2023-06-011

OAAI

The Impact of the CYP2D6 Enhancer Single Nucleotide Polymorphism on CYP2D6 Activity

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2021-11-306

Is this the end for ranitidine? NDMA presence continues to confound

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2021-05-0212

OAAI

Pediatric Clinical Endpoint and Pharmacodynamic Biomarkers: Limitations and Opportunities

PEDIATRIC DRUGS

IF3.3

2020-01-092

PREAI

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2019-04-13141

OAAI

Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics

JOURNAL OF PERSONALIZED MEDICINE

IF3

2018-04-17108

OAAI

Genetic Determinants of Fetal Opiate Exposure and Risk of Neonatal Abstinence Syndrome: Knowledge Deficits and Prospects for Future Research

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2015-07-2220

OAAI

Jean Dinh

个人简介

教育背景

工作经历

荣誉奖项

研究方向